Ampersand Biomedicines
Ampersand Biomedicines is a biopharmaceutical company that focuses on developing innovative programming therapeutics aimed at targeting diseases directly at their site of occurrence. The company employs its Address, Navigate, Design (AND)™ Platform to create localized treatments that enhance precision in disease management. By integrating a localizing element with a carefully selected actuator for disease modification, Ampersand Biomedicines enables researchers to address a broad spectrum of diseases across various body systems. This approach allows for a tailored therapeutic response, potentially improving the efficacy of treatments and advancing the field of precision medicine.
1 past transactions
AbCheck
Acquisition in 2024
AbCheck is a biotechnology company specializing in antibody discovery and optimization for therapeutic applications. Founded in 2009 as a spin-out from Affimed's technology discovery platform, it operates as a wholly owned subsidiary of Affimed GmbH. The company offers a flexible business model that includes drug candidates through discovery collaborations and strategic research partnerships, often under royalty-free agreements. AbCheck utilizes a range of techniques, including de novo antibody discovery from animals and the use of humanized libraries cloned from immunized rabbits, to generate target-specific human antibody domains. These domains can be adapted into various therapeutic formats, primarily focusing on developing innovative solutions for cancer immunotherapies.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.